What’s Going On With Affirm Holdings Stock?

Affirm Holdings Inc (NASDAQ: AFRM) shares are trading lower Wednesday after Upstart Inc (NASDAQ: UPST) shares tumbled on worse-than-expected financial results.

Affirm Holdings Inc (NASDAQ:AFRM) shares are trading lower Wednesday after Upstart Inc (NASDAQ:UPST) shares tumbled on worse-than-expected financial results. Affirm is due to report its quarterly results after the bell. 

What To Know: Upstart missed analyst estimates on both the top and bottom line. Revenue of $134.56 million missed estimates of $140.26 million. A loss of 5 cents per share missed estimates for a loss of 2 cents per share.

Total revenues were down 14% year-over-year. Fee revenue was down 18%. 

Upstart said lending partners originated 114,464 loans across its platform in the quarter, down 34% year-over-year. Conversion on rate requests was 9.5% in the quarter, down from 9.7% in the prior year’s quarter. 

Both Upstart and Affirm offer lending services. Upstart operates an AI lending platform partnering with banks and credit unions to expand access to affordable credit. Affirm offers a platform for digital and mobile-first commerce.

Affirm is set to announce its third-quarter results Wednesday after the close. The company is expected to report a loss of 70 cents per share and revenue of $444.44 million, according to estimates from Benzinga Pro.

See Also: Users Are Loving Roblox – Company Clocks 20% Jump in Daily Active Users, Stock Soars

AFRM Price Action: Affirm shares were down 5.7% at $20.67 at the time of publication, according to Benzinga Pro.

Photo: courtesy of Affirm.

Total
0
Shares
Related Posts
Read More

Travere Therapeutics Announces Confirmatory Data From The Phase 3 PROTECT Study Of FILSPARI Demonstrating Long-Term Kidney Function Preservation In IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint Versus Active Control, Irbesartan

FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) [p= 0.058] and eGFR chronic slope (1.1 mL/min/1.73m2 per year) [p=0.037]. Patients

TVTX